FDA Fast Tracks New Pleural Mesothelioma Drug
The U.S. Food & Drug Administration (FDA) has decided to fast track SELLAS™ Life Sciences’ new drug Galinpepimut-S to treat pleural mesothelioma
Category: Memorial Sloan-Kettering Cancer Center
Epizyme Testing New Mesothelioma Treatment with Phase Two Clinical Trial
Biopharmaceutical company Epizyme, Inc. is starting a new phase two clinical trial using tazemetostat as a treatment for mesothelioma cancer.
Study Says Drug “Cocktail” Could have Huge Impact on Cancer Treatment
Some scientists believe combination therapies such as those used for AIDS patients could eventually cure cancer